Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: Andrew H who wrote (10484)	11/12/1998 3:33:00 PM
From: Heroic	Read Replies (1) \| Respond to of 119973

CTII has much more potential than GERN for a move.

To: Andrew H who wrote (10484)	11/12/1998 3:34:00 PM
From: SalmonMan	Respond to of 119973

Monday's CTII news: LINCOLN, R.I., Nov 9 (Reuters) - CytoTherapeutics, Inc., adeveloper of gene and cell-based drugs, said Monday the U.S.Patent Office has allowed its patent application for the use ofits encapsulated cell technology to treat eye diseases. The company said encapsulated-cell technology is designedto treat serious ailments by delivering therapeutic substancesdirectly to body part where they are needed. CytoTherapeutics stock was up 9/32 at 2-1/8 in middaytrading on the the Nasdaq Stock Market on a volume of 1.4million shares -- an estimated 10 times its average tradingvolume. The company said the patent provides it with broad coverageand a "clear commercial pathway" to develop products to treat anumber of serious eye disorders that are poorly treated oruntreatable. The company said the allowed patent covers methods fordelivering one or more biologically active molecules to the eyethrough encapsulated cell implants placed intraocularly,circumventing the blood-retina barrier, or periocularly. The company said its encapsulated cell implant technologypotentially avoids problems such as toxicity and toleranceassociated with other forms of drug delivery because the agentis surgically placed in the body to deliver a desiredtherapeutic substance directly where it is needed. ((-- New York Newsdesk (212) 859-1700)) REUTERS

To: Andrew H who wrote (10484)	11/12/1998 10:12:00 PM
From: Bradpalm1	Read Replies (1) \| Respond to of 119973

<<The comparison with thalidomide, however, shows the need for a new PR person>> Not really, Andrew. Thalidomide is actually an amazing drug which is now being tested for multiple conditions, metastatic cancer being one of them. It has anti-angiogenesis properties like endostatin and angiostatin but is being utilized in some protocols for refractory metastatic colon carcinomas right now. A better anti-angiogenesis candidate at this time is AGPH's AG3340 which is apparently showing tremendous benefit in early Phase II/III trials on non-small cell cancer patients. Something is shrinking these tumors at an incredible rate although the investigators are blinded at the present time. All of this points to some trouble for ENMD, I believe. Accusations such as those made today by the WSJ carry a lot of weight in the medical community and it may be MONTHS before they can be unequivocally refuted. Folkman may be of Nobel caliber but presently the emperor may have no clothes to speak of. Bradpalm1